About Clene
Clene (NASDAQ:CLNN) is a biopharmaceutical company focused on the development of unique therapies for neurodegenerative diseases. It harnesses nanotechnology to create products aimed at enhancing the cellular energy metabolism, a critical aspect of combating conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease. One of its flagship projects is the development of CNM-Au8, an investigational drug designed to improve neuronal survival. Clene's mission revolves around pioneering novel treatments that can significantly alter the course of neurodegenerative illnesses, offering hope and improving the quality of life for patients worldwide. Through ongoing clinical trials and research collaborations, Clene aims to unlock new possibilities in medical science, demonstrating their commitment to innovation and the well-being of individuals facing these challenging diseases.
Snapshot
Operations
Produtos e/ou serviços de Clene
- CNM-Au8, an investigational nanocatalyst aiming to improve neurological function in diseases such as multiple sclerosis and Parkinson's.
- CNM-ZnAg, a potential treatment targeting infectious diseases by leveraging antimicrobial properties of zinc and silver.
- CNM-AgZn17, designed to enhance wound healing by promoting tissue regeneration and reducing infection risk.
- Research in nanotechnology-enabled drug delivery systems, aiming for higher efficacy and lower side effects in various therapies.
- Development of proprietary nanocatalysis process technology to streamline production of nanoscale materials for diverse therapeutic applications.
- Collaboration with academic and industry partners to discover novel therapeutic targets and pathways for neurodegenerative and other chronic diseases.
equipe executiva do Clene
- Mr. Robert Etherington MBACEO, President & Director
- Mr. Morgan R. Brown CPA, M.B.A.Chief Financial Officer
- Mr. Mark G. Mortenson ESQ.Chief Science Officer
- Mr. Jerry Miraglia J.D.General Counsel & Corporate Secretary
- Ms. Mary Anne McneilHead of Human Resources
- Mr. Michael T. HotchkinChief Development Officer
- Dr. Benjamin M. Greenberg M.D., M.H.S.Head of Medical